Semaglutide and Blood Pressure: What the Research Shows

If you are managing your weight with semaglutide and your healthcare provider is also watching your blood pressure, there is a reason those two conversations keep coming up together. The clinical research has documented a meaningful connection between semaglutide use and blood pressure changes. Understanding what the trials actually show helps set realistic expectations and gives you better questions to ask your provider.

This article covers what large-scale clinical trials have found about semaglutide and blood pressure, the proposed mechanisms behind these effects, practical context for what you might realistically expect, and why semaglutide is not a replacement for blood pressure medication without your provider's guidance.

*Compounded semaglutide is not FDA-approved. This article is for educational and informational purposes only. It does not constitute medical advice. Consult your licensed healthcare provider before starting, stopping, or adjusting any medication.*

---

Why Blood Pressure Matters in the Context of Weight Management

High blood pressure (hypertension) and obesity frequently occur together. Excess body weight contributes to elevated blood pressure through several pathways: increased blood volume, higher cardiac output, insulin resistance, and elevated levels of inflammatory markers. For many people living with obesity, managing weight is closely linked to managing cardiovascular risk.

This overlap means that when a medication like semaglutide produces significant weight loss, improvements in blood pressure are often part of the picture. But researchers have also asked whether semaglutide has cardiovascular effects that go beyond what weight loss alone would explain. The answer, based on recent large trials, appears to be yes.

---

What Major Clinical Trials Show

The STEP-1 Trial: Semaglutide for Weight Loss

The STEP-1 trial (Wilding et al., 2021) is the foundational phase 3 trial for semaglutide 2.4 mg weekly in adults with obesity or overweight without type 2 diabetes. It enrolled 1,961 adults and ran for 68 weeks, with body weight as the primary endpoint and a range of cardiometabolic markers as secondary endpoints.

Participants taking semaglutide lost an average of 14.9% of their body weight, compared with 2.4% in the placebo group. Blood pressure was among the secondary outcomes tracked throughout the trial.

Systolic blood pressure (the top number in a reading) improved meaningfully in the semaglutide group compared to placebo. Participants also showed improvements across related cardiovascular risk factors including waist circumference, fasting blood glucose, and lipid profiles. These results were consistent with the weight loss seen, though the trial also noted that cardiometabolic improvements appeared proportional to the degree of weight reduction.

Citation: Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185

The SELECT Trial: Cardiovascular Outcomes in Obesity Without Diabetes

The SELECT trial (Lincoff et al., 2023) was a landmark study that specifically set out to answer whether semaglutide reduces major adverse cardiovascular events in people with obesity who do not have diabetes. This distinction matters because prior cardiovascular outcomes trials for GLP-1 medications had largely been conducted in patients with type 2 diabetes.

The SELECT trial enrolled 17,604 adults with pre-existing cardiovascular disease and a BMI of 27 or higher, but without diabetes. Participants received weekly semaglutide 2.4 mg or placebo for a mean follow-up period of approximately 40 months. The primary outcome was major adverse cardiovascular events: heart attack, stroke, or cardiovascular death.

Semaglutide reduced the primary endpoint by 20% compared to placebo. This was a statistically significant result that drew significant attention from cardiologists and endocrinologists.

Secondary analyses from SELECT also documented changes in blood pressure. Systolic blood pressure was reduced in the semaglutide group, with reductions persisting across the multi-year follow-up period. The trial provides evidence that semaglutide's cardiovascular effects are not entirely explained by its glucose-lowering properties, since participants were non-diabetic.

Citation: Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131

SUSTAIN-6: Cardiovascular Outcomes in Type 2 Diabetes

The SUSTAIN-6 trial (Marso et al., 2016) evaluated cardiovascular outcomes in patients with type 2 diabetes at high cardiovascular risk. This was an earlier and important study that helped establish the cardiovascular safety and potential benefit of semaglutide.

Among 3,297 participants, semaglutide reduced the rate of major adverse cardiovascular events by 26% compared to placebo. Blood pressure and lipid parameters improved alongside the primary cardiovascular endpoint. SUSTAIN-6 helped lay the groundwork for the later SELECT trial by suggesting that semaglutide's cardiovascular effects extended to people across different risk profiles.

Citation: Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186

---

How Semaglutide May Lower Blood Pressure

Researchers have proposed several mechanisms through which semaglutide could reduce blood pressure. These are not fully settled in the literature, but the leading explanations include:

Weight loss and reduced cardiac load. The most straightforward mechanism. As body weight decreases, the cardiovascular system carries less demand. Blood volume decreases, cardiac output normalizes, and the strain on arterial walls reduces. This accounts for a meaningful portion of the blood pressure changes seen in trials like STEP-1.

Natriuresis (sodium and fluid excretion). GLP-1 receptors are present in the kidneys. Animal and human research suggests that GLP-1 receptor activation promotes sodium excretion through the kidneys, which reduces fluid retention and can lower blood pressure. This is a mechanism independent of weight loss.

Reduced arterial stiffness. Some research suggests GLP-1 agonists may reduce arterial stiffness over time. Stiffer arteries require the heart to work harder to push blood through, raising systolic pressure. Reducing stiffness could contribute to sustained blood pressure improvements.

Anti-inflammatory effects. Chronic low-grade inflammation is associated with elevated blood pressure and cardiovascular disease. GLP-1 receptor agonists including semaglutide appear to have anti-inflammatory properties. Whether this directly reduces blood pressure is still being studied, but the broader cardiometabolic picture is consistent with this pathway.

None of these mechanisms operates in isolation. The blood pressure reductions seen in clinical trials are almost certainly the result of multiple overlapping effects rather than any single pathway.

---

How Much Blood Pressure Reduction Can You Realistically Expect?

Clinical trial data is useful for understanding population-level averages, but individual results vary considerably. Several factors affect how much blood pressure changes for a given person on semaglutide:

Starting blood pressure. People who enter treatment with higher baseline blood pressure tend to see larger absolute reductions. Someone who is normotensive at baseline (normal blood pressure) may see little to no change.

Degree of weight loss. Larger weight loss tends to correlate with more substantial blood pressure improvement. Since individual weight loss responses to semaglutide vary, blood pressure changes vary accordingly.

Concurrent medications. Many people taking semaglutide are already on antihypertensive medications. Blood pressure changes may require medication adjustments, which is something your provider needs to monitor.

Lifestyle factors. Diet quality, sodium intake, physical activity level, and sleep all influence blood pressure. Semaglutide works best in combination with lifestyle changes rather than as a standalone intervention.

The blood pressure improvements seen in SELECT and STEP trials are meaningful at a population level, but they are not guaranteed for every individual, and the magnitude in most participants was modest rather than dramatic.

---

Does Semaglutide Replace Blood Pressure Medications?

No. Semaglutide is not a substitute for prescribed antihypertensive therapy. If you are currently taking medication to manage high blood pressure, do not adjust or stop that medication without discussing it with your provider first.

That said, some people who achieve significant weight loss while taking semaglutide do work with their providers to reduce doses or discontinue antihypertensive medications over time. This is an individualized decision based on monitored blood pressure readings, not something to pursue without medical guidance.

Your provider will likely track your blood pressure regularly as part of monitoring your response to treatment. If your blood pressure decreases significantly, they may suggest adjustments to your antihypertensive regimen.

---

What to Monitor During Treatment

If you are taking semaglutide and managing blood pressure, here are practical considerations for working with your provider:

Regular blood pressure checks. Track your blood pressure at home if possible, using a validated home monitor. Log readings with the time of day, since blood pressure varies throughout the day. Bring this record to your provider appointments.

Watch for symptoms. Some people experience dizziness or lightheadedness when blood pressure drops quickly, particularly when changing positions (a condition called orthostatic hypotension). Report these symptoms to your provider.

Medication review at follow-ups. At each provider check-in, make sure blood pressure medications are reviewed in the context of your current readings and weight loss progress.

Sodium awareness. Reducing dietary sodium can complement the blood pressure effects of semaglutide and weight loss. The American Heart Association recommends no more than 2,300 mg of sodium per day for most adults.

---

Important Safety Information

Semaglutide has side effects that are important to be aware of. The most commonly reported are gastrointestinal: nausea, vomiting, diarrhea, and constipation are frequent, particularly during dose titration. Most people find these improve over time as the body adjusts.

Semaglutide carries a boxed warning about a possible risk of thyroid C-cell tumors based on animal studies. It is not approved for use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Pancreatitis has been reported in patients taking GLP-1 receptor agonists. If you experience severe abdominal pain that does not resolve, seek medical attention.

This is not a complete list of risks. Your licensed healthcare provider is your best resource for understanding whether semaglutide is appropriate for your individual health history.

---

The Bottom Line

The clinical trial evidence shows that semaglutide can produce meaningful improvements in blood pressure as part of its broader cardiometabolic effects. The STEP-1 trial established these improvements in the context of weight loss treatment. The SELECT trial extended the evidence to show significant reductions in cardiovascular events in people with obesity and established heart disease who did not have diabetes. SUSTAIN-6 contributed earlier supporting evidence in a high-risk type 2 diabetes population.

These effects appear to come from a combination of weight loss, direct renal effects on sodium excretion, and possibly other anti-inflammatory and vascular pathways. The degree of benefit varies considerably by individual and is not guaranteed.

Semaglutide is not a blood pressure medication. It is a prescription weight management treatment that, for many people, also has positive effects on cardiovascular risk factors including blood pressure. These benefits are best realized in combination with lifestyle changes and under the supervision of a licensed provider.

If managing blood pressure is part of your health picture, bring that up directly with your provider when discussing semaglutide as an option.

---

Ready to explore your options? [Check your eligibility](/assessment) to see if a medically supervised weight loss program is right for you.

---

*This article is for educational purposes only and does not constitute medical advice. Individual results vary. Compounded semaglutide is not FDA-approved. All treatment decisions should be made in consultation with a licensed healthcare provider.*

*Managed by Prescriva LLC, doing business as Prescriva. Prescriva is a Management Services Organization (MSO) and does not provide medical advice or prescribe medications directly.*

---

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. PMID: 33567185

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24):2221-2232. PMID: 37952131

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *N Engl J Med.* 2016;375(19):1834-1844. PMID: 27633186

1. Seighali N, et al. Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis. *BMC Pharmacol Toxicol.* 2026. PMID: 42163419